- Home
- ATOS vs DTF Comparison
ATOS vs DTF Comparison
Compare ATOS & DTF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ATOS | DTF |
|---|---|---|
| Founded | 2009 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.3M | 80.3M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | ATOS | DTF |
|---|---|---|
| Price | $4.24 | $11.56 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $31.67 | N/A |
| AVG Volume (30 Days) | ★ 256.9K | 21.1K |
| Earning Date | 03-24-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.64% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.44 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $24.34 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.76 | $10.29 |
| 52 Week High | $19.35 | $11.19 |
Technical Indicators
Market Signals| Indicator | ATOS | DTF |
|---|---|---|
| Relative Strength Index (RSI) | 65.41 | 71.40 |
| Support Level | $3.76 | $11.48 |
| Resistance Level | $5.54 | $11.52 |
| Average True Range (ATR) | 0.48 | 0.05 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 49.34 | 100.00 |
Price Performance
Historical ComparisonAbout ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About DTF DTF Tax-Free Income 2028 Term Fund Inc.
DTF Tax-Free Income 2028 Term Fund Inc is a diversified closed-end management investment company. The Fund's investment objective is current income exempt from regular federal income tax consistent with the preservation of capital. It seeks to achieve its investment objective by investing mainly in a diversified portfolio of investment-grade tax-exempt obligations.